Citius Oncology, Inc. (CTOR): Insider Trading, Congress Trades & Research | Tormere

CTOR

$0.55-0.55%visit website

CITIUS ONCOLOGY, INC.

Market Cap

$51M

Live price × SEC shares (Aug 13, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

3.43

46mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

1.3

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q4 FY2025 Sep 30, 2025	Q1 FY2026 Dec 31, 2025	Q2 FY2026 Mar 31, 2026	Q3 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue		3,944	1,667	1,494
Cost of revenue		789	329	492
Gross profit		3,155	1,338	1,002
Research & development	1,076	1,018	1,079	218	3,392
Total operating expenses	4,712	8,407	29,952	9,719	52,789
Operating income	(4,712)	(5,252)	(28,614)	(8,717)	(47,294)
Interest expense	57	46	33	232	368
Pretax income	(4,732)	(5,270)	(26,841)	(9,031)	(45,874)
Income tax	264	264	(231)	(107)	190
Net income	(4,997)	(5,534)	(26,610)	(8,924)	(46,064)
EPS (basic) ($)		(0.06)	(0.27)	(0.08)	(0.48)
EPS (diluted) ($)		(0.06)	(0.27)	(0.08)	(0.48)
Weighted avg. shares (basic)		87,462	100,027	107,890
Weighted avg. shares (diluted)		87,462	100,027	107,890

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 14, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 14 more quarters, back to Sep 2021, with Tormere Pro.

Signals

Insider Velocity

no recent activity

purchases / sales, 90d

Market & Alt Data

News

15

recent articles

Citius Pharmaceuticals, Inc. · 2026-06-04

No Form 4 transactions on record.

Recent News

In a cancer-treatment study, 13 of 41 patients had less itching for at least four weeks.

Stock Titan · 2026-11-04

Citius Oncology's Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe

Yahoo Finance · 2026-11-04

Citius Oncology (CTOR) Stock Forecast & Analyst Ratings

Moomoo · 2026-11-02

Citius Oncology, Inc. (CTOR) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada · 2026-10-31

After-Hours Movers: SNTI, BRAI, CLS Rise; SPRC, DVLT Fall

ChartMill · 2026-10-26

12 Health Care Stocks Moving In Monday's After-Market Session

Benzinga · 2026-10-26

Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026

Yahoo · 2026-10-26

Citius Oncology Reports Preliminary Q4 FY2026 LYMPHIR Wholesaler Unit Sales More Than Doubling 120% To 792 Units, With 950 Institutional Vial Orders And 54 Institutions Ordering The CTCL Treatment

Benzinga · 2026-10-26

54 institutions have ordered LYMPHIR, a cancer drug, up from 44 as of Aug. 14.

Stock Titan · 2026-10-26

Citius (CTOR) Up +5.96% — Is There More Room to Run? 2026-10-21 - Negative Gamma

https://www.siam.in/ · 2026-10-21

Citius Oncology, Inc. (CTOR) Stock Price & News

Syfe · 2026-10-19

Citius Pharmaceuticals to Participate in October 2026 Investor Conferences

Yahoo · 2026-10-12

Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum

Yahoo Finance · 2026-08-17

Breakeven On The Horizon For Citius Oncology, Inc. (NASDAQ:CTOR)

Simply Wall St · 2026-08-15

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Yahoo Finance · 2026-08-12

Informational purposes only, not investment advice.

Corporate Events (8-K)

2 filings in 12 months · 0 with priority itemsFull history →

Filed	Items	Filing
Nov 4, 2026 accepted 4:30 PM ET	8.01Other events	SEC ↗
Oct 26, 2026 accepted 4:05 PM ET	2.02Earnings release	Document SEC ↗